Aberdeen Income Credit Strategies Fund (ACP) Stock Price

5.47 ▲ +0.09 (+1.67%)
Open: 5.39 Vol: 734.9K Day's range: 5.39 - 5.48 Nov 28, 16:00 EST
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
ACP Technical Analysis
5 mins 30 mins Hourly Daily Weekly
BUY BUY BUY BUY SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 5.47▲ 5.45▲ 5.44▲ 5.34▲ 5.46▲
MA10 5.46▲ 5.42▲ 5.40▲ 5.36▲ 5.57▼
MA20 5.45▲ 5.39▲ 5.36▲ 5.44▲ 5.75▼
MA50 5.42▲ 5.32▲ 5.32▲ 5.59▼ 5.83▼
MA100 5.38▲ 5.33▲ 5.40▲ 5.77▼ 6.23▼
MA200 5.31▲ 5.41▲ 5.48▼ 5.80▼ 6.85▼
  5 mins 30 mins Hourly Daily Weekly
MACD 0.000▼ 0.007▲ 0.014▲ 0.008▲ -0.041▼
RSI 74.158▲ 86.403▲ 79.481▲ 50.300▲ 38.519▼
STOCH 95.833▲ 98.810▲ 99.167▲ 47.035     21.146    
WILL %R 0.000▲ 0.000▲ 0.000▲ -17.073▲ -59.036    
CCI 87.246     121.986▲ 158.398▲ 39.289     -106.952▼
Latest Filters Detected On ACP
RSI $ACP RSI(14) Crossed Above 50 Set Alert
▲ MACD $ACP MACD(12,26,9) Crossed Above Signal Line Set Alert
MA $ACP Price Crossed Above MA(26) Set Alert
MA $ACP Price Crossed Above MA(13) Set Alert
Aberdeen Income Credit Strategies Fund News
BofA Expands Veteran Support with $350k Grant
Monday, November 10, 2025 06:59 AM
CHARLOTTE, N.C., Nov. 10, 2025 /PRNewswire/ -- Bank of America (BofA) today announced a $350,000 grant to American Corporate Partners (ACP), a commitment that will support 250 mentorships for veterans ...
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
Thursday, September 25, 2025 07:49 AM
Shares of Acadia Pharmaceuticals ACAD lost 9.9% on Wednesday after the company announced a disappointing update from a late-stage study of its investigational candidate, intranasal carbetocin (ACP-101 ...
Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint
Wednesday, September 24, 2025 04:00 AM
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin ...
ACP historical stock data
date open high low close volume
28/11/25 5.39 5.48 5.39 5.47 734,900
26/11/25 5.35 5.38 5.33 5.38 651,900
25/11/25 5.30 5.34 5.30 5.34 878,300
24/11/25 5.22 5.30 5.21 5.30 1,089,300
21/11/25 5.15 5.22 5.13 5.22 1,029,100
20/11/25 5.33 5.36 5.23 5.23 916,100
19/11/25 5.40 5.41 5.32 5.32 741,200
18/11/25 5.45 5.46 5.38 5.38 661,600
17/11/25 5.47 5.48 5.44 5.47 711,600
14/11/25 5.45 5.50 5.42 5.50 542,700
Quote Details
52wk Low:4.92
52wk High:6.50
Vol:734.9K
Avg Vol(3m):12.7M
1Y Chng:-8.99%
1M Chng:-1.80%
Add to Watch List
More Information
Sector N/A
Index N/A
Market Cap. 224.29M